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Abstract
Findings of polymerase chain reaction (PCR) studies of cytomegalovirus (CMV) and Ep-
stein-Barr virus (EBV) and breast cancer vary, making it difficult to determine whether either,
both, or neither virus is causally associated with breast cancer. We investigated CMV and
EBV in paired samples of breast cancer and normal breast tissue from 70 women using
quantitative PCR. A serum sample from each woman was tested for CMV and EBV IgG. To
place our results in context, we reviewed the existing literature and performed a meta-analy-
sis of our results together with previous PCR studies of EBV, CMV, and breast cancer. Of
the serology samples, 67 of 70 (96%) were EBV IgG positive and 49 of 70 (70%) were CMV
IgG positive. QPCR detected EBV in 24 (34%) of the tumour and 9 (13%) of the paired nor-
mal specimens and CMV in 0 (0%) of the tumour and 2 (3%) of the paired normal speci-
mens. Our findings, together with earlier results summarised in the meta-analysis, suggest
several possibilities: variable findings may be due to limitations of molecular analyses; ‘hit
and run’ oncogenesis may lead to inconsistent results; one or both viruses has a role at a
later stage in breast cancer development; infection with multiple viruses increases breast
cancer risk; or neither virus has a role. Future studies should focus on ways to investigate
these possibilities, and should include comparisons of breast cancer tissue samples with
appropriate normal tissue samples.
Introduction
Breast cancer is the most commonly diagnosed cancer in women worldwide.[1] Several human
cancers can be caused by viruses and a virus, mouse mammary tumour virus (MMTV), causes
breast cancer in mice.[2] We hypothesised that late exposure (in adulthood rather than in
childhood) to a common virus such as CMV or EBV may cause breast cancer.[3, 4] Cytomega-
lovirus is ubiquitous in human populations but patterns of exposure differ among countries.
Breast cancer incidence is low in those countries where most people seroconvert in childhood
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and where therefore nearly 100% of adults are CMV-seropositive. Breast cancer incidence is
highest in countries where exposure to CMV may occur late, with a strong inverse correlation
(Pearson correlation coefficient −0.79, p< 0.0001) between breast cancer incidence and the
proportion of CMV-seropositive adults in various countries.[3]
In a case-control study of CMV and EBV and breast cancer,[5] mean CMV IgG levels were
higher in cases than controls, with an adjusted odds ratio (OR) per unit increase in CMV IgG
of 1.46 and 95% confidence interval (CI) 1.06–2.03. To investigate whether CMV or EBV IgG
levels were elevated before the diagnosis of breast cancer, a nested case-control study with two
serum samples taken at least four years before the diagnosis of breast cancer in cases, and sam-
ples matched for duration of storage from controls, were tested for CMV and EBV IgG.[6] The
risk of breast cancer, adjusted for parity, was greater per unit difference in CMV IgG between
samples: OR 1.7 (95% CI 1.1–2.5). In an analysis restricted to parous cases and age-matched
parous controls, the OR for seroconversion between samples in the same individual, adjusted
for parity and age at first birth, was 9.7 (95% CI 1.2–77.3). Both case-control studies found that
higher IgG levels (possibly indicating late exposure to CMV) are associated with breast cancer
but there was no association between EBV IgG levels and breast cancer.
CMVmay have a role as an ‘oncomodulator’ in changing the tumour microenvironment as
well as in initiation and promotion of tumour cells.[7–10] PCR has been used to investigate
CMV in breast tumour and normal tissue,[11–13] with CMV genetic material found in a
higher proportion of tumour tissue than normal tissue. The role of EBV in breast cancer is con-
troversial. [14–19] A case-control study linked delayed EBV infection with breast cancer,[4]
and a recent study using QPCR suggested EBV may be a marker of biological aggressiveness in
breast cancer.[20] Three earlier studies also suggested that breast cancer may be associated
with late infection and/or immune response to late infection.[21–23] There is evidence for
both CMV and EBV as disruptors of telomere maintenance, which may play a role in cancer
development. [24, 25] However, two earlier studies using QPCR of EBV and breast cancer
found very low levels of EBV DNA in breast cancer tissue[26, 27] and a recent study using
immunohistochemistry (IHC) and in situ hybridization (ISH) found EBV in infiltrating lym-
phocytes in breast cancer tissue but not in malignant cells.[28]
Using quantitative PCR (QPCR), we compared CMV and EBV genetic material in paired
samples of breast cancer and histologically normal breast tissue from 70 women. We also mea-
sured serum CMV and EBV IgG levels. In addition, we reviewed the existing literature on PCR
studies of EBV and/or CMV and breast cancer and performed a meta-analysis of our results to-
gether with earlier findings for EBV, CMV, and breast cancer.
Materials and Methods
Tissue and serum samples collected and stored by the Cancer Society Tissue Bank, Christ-
church (CSTB) were analysed. All patients attending Christchurch Hospital, New Zealand, for
cancer-related surgery are potential CSTB donors. Written informed consent (Ethics Commit-
tee Approvals 02.06.98/5.11.09) was obtained for the collection, storage, and use of all samples.
Standard CSTB procedures were followed; these include culturally appropriate tissue handling
and disposal protocols. [29] Each sample in the CSTB has a computer-generated unique identi-
fier to protect patient confidentiality and is accompanied by extensive clinicopathological data
and recent follow-up data. Approval for this project was granted by the University of Otago
Human Ethics Committee (UOHEC 13/079) and the Canterbury Tissue Bank Board
(13.03.2013).
Serum was prepared from blood drawn by venepuncture at least 24 hours prior to surgery
and stored at -80°C. Breast tissue from surgery was evaluated by an experienced histopathologist,
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who selected representative tumour and histologically normal samples for storage. Normal tissue
samples were dissected from areas that showed no fibrosis and were at least 70–100 mm away
from the tumour. Fresh tissues were placed in a storage cryovial, snap frozen in liquid nitrogen,
and stored at -80°C in<50 minutes from surgical removal.
Sample-size calculations showed that 60 paired samples would allow us, using QPCR, to de-
tect a difference between breast cancer and normal breast DNA in mean copies per ml of ± 0.37
standard deviations, with 95% confidence and 80% power. We prepared 70 paired samples to
allow for failure of processing. The breast cancer samples included a range of grade, receptor sta-
tus, and disease stage (Table 1 shows the characteristics of the patients and tissue samples).
DNA isolation and quantitative PCR (QPCR)
DNA from invasive breast cancer tissue and from paired normal breast tissue was extracted
from frozen samples. DNA was isolated using the QIAamp DNAmini kit (Qiagen) using the
addition of polyA oligonucleotides (Roche Diagnostics) as described by the manufacturer. The
manufacturer recommends that carrier DNA (for example poly dA) is used when the sample is
low-copy (when<10,000 copies are present). This step was important for efficient recovery of
viral genomes. Quantitation of CMV and EBV DNA was carried out using CMV- and EBV-
specific primer sequences targeted to the conserved pp65[30] and EBNA-1 (Qiagen Artus EBV
TM PCR kit) regions, respectively. The DNA sequence of primer pairs and Taqman probes de-
signed for each target region are shown in Table 2. The CMV and EBV quantitation standards
Table 1. Patient and tumour characteristics.
Age of Patient at Surgery Percent
25–29 1.3
30–34 2.6
35–39 5.2
40–44 20.8
45–49 7.8
50–54 13.0
55–59 3.9
60–64 9.1
65–69 6.5
70–74 7.8
75–79 6.5
80–84 6.5
85+ 9.1
Tumour Grade Percent
1 8.5
2 29.6
3 62.0
Histologic Type Number
Infiltrating ductal carcinoma 70
Normal (paired samples from women with breast cancer) 70
Surgical Type Percent
Mastectomy 8.1
Mastectomy and axillary dissection/clearance 82.5
Wide local excision and axillary dissection 9.5
doi:10.1371/journal.pone.0118989.t001
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were created by a plasmid construct of the PCR product and CMV copy number was deter-
mined by droplet digital PCR (Bio-rad). We used reference human DNA sequence from the
ALB gene—which is known to lack germline copy number variation—to validate DNA isola-
tion and perform comparative analysis between normal and breast cancer tissue samples. All
PCR reactions were performed on an ABI 7500 real-time PCR system (Applied Biosystems,
Life technologies) and null PCR results were validated by an inhibitor control target included
in the EBV kit.
Serology
A stored serum sample from each woman was extracted to establish CMV and EBV IgG seros-
tatus and compare these with the QPCR results. Serum samples were tested at Canterbury
Health Laboratories for seropositivity to CMV and EBV using standard enzyme immunoassays
(Euroimmun, Luebeck, Germany) for CMV IgG and EBV viral capsid antigen (VCA) IgG,
with measurement in units of optical density.
Statistical analysis
Random effects meta-analysis was performed on the proportions of samples positive for EBV
and CMV respectively rather than relative risks, because only six studies (including ours) in-
cluded paired normal samples. Proportions had 95% confidence intervals derived from the
Normal approximation to the binomial with 0.5 added to zero counts. Estimates of average
proportion positive were calculated for all studies and for each assay type that was used in mul-
tiple studies; however, there was considerable heterogeneity in both EBV and CMV analyses
(I2 = 98.6% and 99.6% respectively). Analysis was performed in R 3.1.1 (Vienna, Austria) using
the Metafor package.[31]
Results and Discussion
The age range of the women studied was 25–88, with most in the 40–54 year age-group
(Table 1). All had infiltrating ductal carcinoma, with 62% high-grade tumours. The vast major-
ity of tissue samples (90.5%) were from women who had undergone mastectomy, because we
needed invasive breast cancer tissue and normal breast tissue samples that were separated by at
least 70mm. Most tissue samples from wide-local excisions were unsuitable for obtaining
paired samples because there was not enough normal tissue available that was>70mm from
the tumour.
QPCR detected EBV in 24 (34%) of the 70 tumour specimens and in 9 (13%) of the paired
normal specimens. CMV was detected in 0 (0%) of the 70 tumour specimens and in 2 (3%) of
the paired normal specimens (Table 3).
EBV positivity was not associated with grade, receptor status, or disease stage.
Table 2. Sequences of primers and probes used for QPCR.
Target Forward primer (5’-3’) Reverse primer (5’-3’) Taqman Probe (5’-3’)
CMV—pp65 GCAGCCACGGGATCGTACT GGCTTTTACCTCACACGAGCATT CGCGAGACCGTGGAACTGCG
EBNA-1 Unpublished* Unpublished* Unpublished*
ALB GCTGTCATCTCTTGTGGGCTGT AAACTCATGGGAGCTGCTGGTT CCTGTCATGCCCACACAAATCTCTCC
* The Artus EBV TM PCR kit primer and probes are proprietary and not made publicly available.
doi:10.1371/journal.pone.0118989.t002
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Sixty-seven of 70 (96%) of the serology samples that corresponded to the paired tissue sam-
ples were EBV IgG positive. Forty-nine of 70 (70%) of the serology samples that corresponded
to the paired tissue samples were CMV IgG positive. In general, CMV seropositive women
were younger (mean age 51) than CMV seronegative women (mean age 62) p<0.01.
Meta-analysis revealed considerable heterogeneity in positivity for both EBV (Fig. 1) and
CMV (Fig. 2) in breast cancer populations. The average positivity for CMV sits between two
modes. Our present study and three previously reported PCR- or QPCR-based studies pro-
duced positive proportions statistically indistinguishable from zero, whereas two found positiv-
ity to be very high or statistically indistinguishable from complete positivity (Fig. 2). All studies
using IHC or ISH found CMV to be present in almost all participants. The mean positivity for
EBV is 26%, (95% CI 20%-31%) with 12 out of 54 (22.2%) studies across all assay types detect-
ing positivity statistically indistinguishable from zero whereas only two (3.7%) studies are con-
sistent with complete positivity.
Published results of PCR analyses of CMV and/or EBV in breast cancer have been inconsis-
tent. In this study, we performed an inhibitor control reaction to validate the null samples and
used a house-keeping gene (ALB)-PCR to ensure DNA quality (amplifiable DNA present). All
samples were positive for ALB DNA amplification, indicating that the results are interpretable
as they stand. We did not use microdissection (which can cause virus levels to be too low to
amplify) and used histologically normal cells with no visible signs of atypia, which meant that
our study avoided some of the limitations of earlier studies. Only four previous studies have
used paired breast cancer and normal breast tissue samples for PCR analysis of EBV[27, 32, 33]
or CMV(13) and our study and one other[34] have included PCR analysis of both viruses in
paired breast cancer and normal breast samples. To place our results in context, we undertook
a comprehensive review of the existing literature on PCR studies of EBV and/or CMV and
breast cancer, together with a meta-analysis. The findings are summarised in S1 Table and in
Figs. 1 and 2 and discussed below.
Of 32 PCR studies of EBV and breast cancer, 22 (69%) had positive results ranging from 2%
to 100% of specimens tested, [11, 14, 16, 18, 20, 26, 32, 35–49] whereas 10 studies (31%) did
not[27, 33, 34, 50–56]. There are fewer PCR studies of CMV and breast cancer. Of seven stud-
ies, six (86%) found positive results, ranging from 7.4% to 100% of specimens tested, [11, 13,
57–60] whereas one study did not detect CMV in any of 54 samples but found EBV in 10% of
the samples[34]. The results from the two studies by Tsai et al have been included once, as
these studies used the same tissue samples.[11, 12] The extreme heterogeneity in the meta-
analysis of CMV and EBV breast cancer studies is of great concern. Firstly, the extreme varia-
tion in positivity invalidates any inferences using mean positivity across breast cancer popula-
tions, particularly for CMV. Secondly, the spread of results between and within assay types,
albeit on different populations, admits the possibility that the assays are not reliable. Again,
this is particularly acute for CMV.
Table 3. Results of QPCR analysis.
Breast cancer tissue Paired normal tissue
Number Percent Number Percent
CMV positive 0 0.0 2 2.9
CMV negative 70 100.0 68 97.1
EBV positive 24 34.3 9 12.9
EBV negative 46 65.7 61 87.1
doi:10.1371/journal.pone.0118989.t003
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Fig 1. Meta-analysis of EBV positivity in breast cancer tissue samples.Random effects meta-analysis
was performed on the proportions of samples that were positive for EBV rather than relative risks, because
only six studies (including ours) included paired normal samples. Proportions had 95% confidence intervals
derived from the Normal approximation to the binomial with 0.5 added to zero counts. Estimates of the
CMV and EBV in Breast Cancer
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The primers used for PCR analysis have differed among studies but this does not explain
the findings for EBV and breast cancer, as some studies using the same primer found positive
results whereas others found null results. Two studies[27, 42] warned about false-positive re-
sults, noting that the PCR result for one lytically infected cell containing several hundred copies
of the EBV genome would be indistinguishable from several hundred cells each containing a
single copy of the genome[42] and that PCR techniques using many cycles of amplification
could detect a single molecule of EBV DNA.[27] There have been fewer PCR studies of CMV
and breast cancer but all that used IE-gene primers have been positive. IE-genes are important
in allowing CMV to escape immunosurveillance and IE proteins have been shown to introduce
average proportion positive were calculated for all studies and for each assay type that was used in multiple
studies. Results of studies that analyzed breast tissue samples for EBV are shown according to the method
of analysis. The overall strength of association for each type of analysis, and the overall strength of
association for all studies are shown at the bottom of the figure. There was considerable heterogeneity in the
EBV analyses (I2 = 98.6%).
doi:10.1371/journal.pone.0118989.g001
Fig 2. Meta-analysis of CMV positivity in breast cancer tissue samples. Random effects meta-analysis was performed on the proportions of samples
that were positive for CMV. Proportions had 95% confidence intervals derived from the Normal approximation to the binomial with 0.5 added to zero counts.
Estimates of the average proportion positive were calculated for all studies and for each assay type that was used in multiple studies. Results of studies that
analyzed breast tissue samples for CMV are shown according to the method of analysis. The overall strength of association for each type of analysis, and the
overall strength of association for all studies are shown at the bottom of the figure. There was considerable heterogeneity in the CMV analyses (I2 = 99.6%).
Footnote to Fig. 2: PCR results for Harkins et al were not included in this meta-analysis because nested PCR was performed on only 8 specimens, all of
which were positive on IHC (please see S1 Table).
doi:10.1371/journal.pone.0118989.g002
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mutations in cellular DNA, [61] whereas pp65 is not required for primary and persistent infec-
tion in animals.[62]
In situ hybridization (ISH) is regarded as superior to PCR because it can differentiate be-
tween viral infections in tumour cells and infection in other cells but its sensitivity and specific-
ity depend on the target used. Positive findings for EBV were less likely with ISH than PCR: of
16 studies of EBV and breast cancer using both ISH and PCR, five (31%) found positive results
with both PCR and ISH,[16, 36, 38, 39, 48] whereas nine (56%) found positive PCR but null
ISH results,[14, 32, 35, 37, 45, 52–54, 56] and two (13%) found null results for both.[27, 51]
One study of CMV and breast cancer, using PCR and ISH, found positive results for both.[13]
Advantages and limitations of analyses for viruses in breast cancer are summarised in Table 4.
The type of specimen tested does not explain differing results for EBV: although 12 (71%)
studies found positive PCR results in formalin-fixed, paraffin-embedded specimens, [17, 35,
37, 38, 40, 43, 45, 47, 48, 54, 56] six did not. [27, 43, 51, 55, 65] One study, using both frozen
and formalin-fixed, paraffin-embedded specimens, was negative with PCR but 5% of speci-
mens were positive with nested PCR.[33] Four studies of CMV using formalin-fixed, paraffin-
embedded specimens found positive results, ranging from 7.4% to 100% of specimens tested,
[13, 57, 59, 60] whereas one study, using frozen samples was positive [11] and our study and
one other, [34] using frozen samples, had null results. One study using fresh breast cancer tis-
sue samples was positive.[58]
Similarly, results are not determined by histologic types of breast tissue (medullary, invasive
ductal, fibroadenoma, normal tissue). A study of fibroadenoma tissue from immunosuppressed
and non-immunosuppressed patients was positive for EBV using PCR but none of the fibroa-
denomas from non-immunosuppressed patients expressed LMP-1 protein, suggesting that
EBV may be associated with fibroadenomas only in immunocompromised patients[41]. It has
been suggested that EBV detected in breast tissue samples is present in lymphocytes rather
than tumour cells[28, 52, 54] but others dispute this [14, 16, 38]. Finding EBV in infiltrating
lymphocytes could be expected if breast cancer is, even in part, a response to an abnormal
immune stimulus.
It has been suggested that geographic differences may partly explain varying findings for
EBV; nasopharyngeal carcinomas (NPC) are usually associated with EBV in populations in
Hong Kong but a lower proportion of EBV-associated NPC is found in European and central
Chinese populations[53]. However, no such pattern appears evident in studies of EBV, CMV,
and breast cancer. Age-standardised incidence rates of breast cancer are highest in Western Eu-
rope, the USA, and Australasia, and lowest in East Asia and the Middle East.[1, 66] Most of the
studies of EBV and CMV were carried out in high-risk countries but there was no clear differ-
ence between high- and low-risk countries, with the majority of studies reporting positive PCR
results. The 10 studies reporting null results included high-risk areas such as the USA, Europe,
and Australia but also lower-risk countries such as Iran and Mexico. Two studies compared re-
sults from different countries: one, comparing results for Egyptian and Iraqi women, found
45% of 40 Egyptian samples and 28% of 50 Iraqi samples positive.[48]; the other included 509
breast cancer samples from countries with varying risks of NPC (which is known to be associ-
ated with EBV), but found no difference in EBV positivity by geography.[16]
Another possibility is that co-infection with multiple viruses increases the risk of breast can-
cer. EBV may be oncogenic in conjunction with other viruses:[49] sequences from more than
one virus (EBV, HPV, and MMTV) were detected in 72% of breast tumour tissue and in 13%
of breast-milk samples from women without breast cancer. Tsai et al[11] using PCR to detect
EBV, CMV, human papilloma virus (HPV), herpes simplex virus (HSV-1 and HSV-2), and
human herpes virus-8 (HHV-8), found that, among viral-gene-positive breast cancer samples,
23% were positive for one virus, 31% were positive for two, 40% were positive for three, and 6%
CMV and EBV in Breast Cancer
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were positive for four viruses. In a reanalysis of these data, [67] DNA belonging to two or more
viruses was more common in breast cancer and fibroadenoma (77% and 100%, respectively)
than DNA from one virus (23% and 0%, respectively), suggesting that multiple viral infections
may be associated with benign or malignant breast tumours. In contrast, Antonsson et al[34]
investigated the prevalence of ten polyomaviruses and two herpes viruses in breast cancer
using QPCR. They failed to detect eight of the 12 viruses (including CMV) in 54 breast cancer
samples tested, with the highest prevalence being EBV (detected in 10% of the samples).
A recent review of the molecular evidence for viruses and human breast cancer examined
the evidence for EBV.[64] This review identified three possible problems with PCR analyses:
false-negative results; false-positive results; and choice of specimens for comparison.[64] False-
negative results may occur because: studies that do not report DNA-quality testing cannot
demonstrate that null results were not due to nucleic acid degradation; laser microdissection
can cause virus levels to be too low to amplify; partial deletion or polymorphism of the viral
gene could hamper hybridization; and loss of the virus during cell division may result in ab-
sence of viral DNA (‘hit and run’ behavior—discussed below). False-positive results could be
caused by the presence of EBV-positive lymphocytes in tumour tissue and use of nested PCR,
which is prone to contamination (although this can also occur with QPCR). The use of paired
tumour and normal specimens was questioned because of the possibility that ‘normal’ samples
may contain atypical cells.
Joshi and Buehring suggested that PCR studies of EBV and breast cancer that targeted
BamH1W found a higher frequency of virus-presence than those targeting EBV-encoded small
RNAs (EBERs),[64] but our review of the literature, which included more recent studies, does
not support this. It has been demonstrated that expression of EBERs in EBV-infected cells in
NPC is not universal, which may explain a low prevalence of positive results for EBERs and
breast cancer, whereas EBNA-1 is always expressed in EBV infections.[68]
It is also possible that EBV and/or CMVmay be associated with breast cancer through
mechanisms that differ from those identified for other virus-associated cancers, including the
Table 4. Advantages and limitations of molecular analyses.
Advantages Limitations
Immunohistochemistry (IHC) Can distinguish virus in tumour cells from virus in
other cells such as lymphocytes.
May lack specificity due to cross-reactivity with cellular proteins
(especially EBV EBNA1).
In-situ hybridization (ISH) Can distinguish virus in tumour cells from virus in
other cells such as lymphocytes.
The sensitivity and specificity of ISH depend on the target (high
sensitivity and specificity for EBV EBERs).
Southern Blot hybridization Permits semi-quantification of viral load. Less sensitive than PCR for detecting viral DNA. Partial deletion
or polymorphism of the viral DNA could prevent hybridization to
viral DNA.
Polymerase chain reaction
(PCR)
Highly sensitive and specific method for detecting
the presence of viral DNA.
Cannot differentiate between cell types (for instance in breast
tumours with lymphocytic infiltrates). Use of laser capture
microdissection (LCM) may cause virus levels to be too low to
amplify using PCR. Possibility of false positive results due to lytic
viral replication.
Nested PCR Highly sensitive and specific method for detecting
the presence of viral DNA, with enhanced
amplification.
Prone to contamination (for example by positive control DNA).
Quantitative polymerase chain
reaction (QPCR)
Highly sensitive and specific method for detecting
the presence of viral DNA, which allows
quantification of viral DNA.
LCM can cause virus levels to be too low to quantify using
QPCR. QPCR may be prone to contamination, but this is less
likely than with standard PCR.
[46, 63, 64].
doi:10.1371/journal.pone.0118989.t004
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ability of the virus to evade immunosurveillance by expressing only a few factors[63] and the
possibility of a ‘hit and run’mechanism where viral episome might be lost from malignant
cells.[44, 46] Similarly, several possible mechanisms for CMV tumorigenesis have been identi-
fied, including the actions of virus-encoded interleukins, activation of telomerase, immunosup-
pression, and persistent infection leading to inflammation and the promotion of malignancy.
[9, 25, 69] Among the studies reviewed, it was rare for EBV or CMV to be detected in 100% of
specimens. It has been suggested for EBV that the ‘hit and run’ hypothesis might explain this,
or that infection with EBV at a late state of tumour development might “enhance oncogenic
properties, such as invasiveness, angiogenesis, and metastasis.”[46] Another plausible explana-
tion is that either EBV or CMV is associated with a specific molecularly defined subset of breast
cancers, a relationship already established for other environmental and host risk factors.[70]
Conclusions
The results of our QPCR study support a possible association between EBV and breast cancer
but not CMV and breast cancer whereas our earlier studies of CMV and EBV IgG levels found
an association between elevated IgG levels and breast cancer for CMV but not EBV.[5, 6]
These findings, together with the results of other studies of EBV and CMV and breast cancer,
suggest several possibilities: [1] limitations of molecular analyses mean that these analyses can-
not confirm whether, one, both, or neither virus is associated with breast cancer; however, sen-
sitivity may be increased by using ISH in addition to PCR; [2] ‘hit and run’ oncogenesis means
that the virus may be absent after the tumour has developed, leading to inconsistent findings;
[3] one or both viruses may have a role at a later stage in the development of breast cancer—
this may explain elevated CMV IgG levels associated with breast cancer; [4] infection with mul-
tiple viruses may increase the risk of breast cancer; and [5] neither virus has a role in breast
cancer development. Future studies should focus on ways to investigate these possibilities and
should include comparisons of breast cancer tissue samples with appropriate normal tissue
samples.
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